Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 12/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354408 | 0.93 | PLA2G2A (0.63) | PLA2G2APTGS2HDAC3HDAC1HDAC8 | |
| SCHEMBL8356920 | 0.92 | PLA2G2A (0.50) | PLA2G2APTGS2PLA2G1B | |
| SCHEMBL8356411 | 0.89 | PLA2G2A (0.49) | PLA2G2APTGS2 | |
| SCHEMBL8360163 | 0.89 | PTGS2 (0.47) | PLA2G2APTGS2HDAC3HDAC1HDAC8 | |
| SCHEMBL8356966 | 0.85 | PLA2G2A (0.49) | PLA2G2APTGS2PLA2G1B | |
| SCHEMBL8359040 | 0.85 | PTGS2 (0.58) | PLA2G2APTGS2HDAC3HDAC1HDAC8 | |
| SCHEMBL8356649 | 0.85 | PTGS2 (0.58) | PLA2G2APTGS2HDAC3HDAC1HDAC8 | |
| SCHEMBL8356294 | 0.84 | PLA2G2A (0.60) | PLA2G2APTGS2PLA2G1B | |
| SCHEMBL8355061 | 0.84 | PLA2G2A (0.41) | PLA2G2APTGS2 | |
| SCHEMBL8360168 | 0.84 | PLA2G2A (0.41) | PLA2G2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5877202-A | Indole derivatives useful to treat estrogen-related neoplasms and disorders | AVENTISUB II INC. | 1999-03-02 | — | — | US | claimed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | claimed |
| EP-0746544-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1995022524-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-24 | — | — | WO | claimed |
| US-5877202-A | Indole derivatives useful to treat estrogen-related neoplasms and disorders | AVENTISUB II INC. | 1999-03-02 | — | — | US | disclosed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0746544-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022524-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-24 | — | — | WO | disclosed |